Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 14/20 | 0.50 |
| ▸ | FGR | P09769 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | TEC | P42680 | 1/20 | 0.50 |
| ▸ | BMX | P51813 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2487499 | 0.89 | BTK (0.63) | BTKFGRSRCTECBMX | |
| SCHEMBL2488092 | 0.84 | BTK (0.62) | BTKFGRSRCTECBMX | |
| SCHEMBL2489542 | 0.79 | BTK (0.73) | BTKFGRSRCTECBMX | |
| SCHEMBL2495112 | 0.78 | BTK (0.64) | BTKFGRSRCTECBMX | |
| SCHEMBL2490453 | 0.77 | BTK (0.74) | BTKFGRSRCTECBMX | |
| SCHEMBL2492653 | 0.76 | BTK (0.64) | BTKFGRSRCTECBMX | |
| SCHEMBL2493558 | 0.76 | BTK (0.64) | BTKFGRSRCTECBMX | |
| SCHEMBL2488898 | 0.76 | BTK (0.64) | BTKFGRSRCTECBMX | |
| SCHEMBL2492458 | 0.76 | BTK (0.65) | BTKFGRSRCTECBMX | |
| SCHEMBL2494014 | 0.76 | BTK (0.65) | BTKFGRSRCTECBMX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301145-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | Gilead Connecticut INc. (US) | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301145-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, SYK, LCK | BTK 1/4885FGR 1105/4885SRC 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.